FRAMINGHAM, Mass. & BOSTON–(BUSINESS WIRE)–Variantyx (www.variantyx.com) today announced the integration of its clinical whole genome testing pipeline with FDNA’s (www.fdna.com) Face2Gene suite of applications. Using its proprietary Genomic Intelligence® platform, Variantyx provides end-to-end clinical diagnostic services for rare genetic disorders based on comprehensive whole genome sequencing (WGS). Integration with Face2Gene technology now enables clinicians worldwide to send information about the phenotypes, syndromes, and genes that correlate with a patient’s facial and clinical analysis to Variantyx directly, speeding analysis and improving variant interpretation.
The Importance of Teaching Face2Gene to Pediatricians
In the world of rare genetic diseases, early diagnosis is often the key to better patient outcomes. However, the diagnostic journey can be long and complex, sometimes taking years before a definitive answer is found. Dr. Bruno Bordest, a Brazilian geneticist who teaches at the Universidade Federal de Mato Grosso, has been working to bridge […]
